{"changeSha256":"dda4bec27e10b776285f0c848c7ac059743955e7511b29a257e323f6172b3b8d","changedAt":"2026-11-15","changedFields":[{"after":"An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide and in registered Phase 3 trials. It is not FDA-approved.","before":"An experimental Novo Nordisk GLP-1 and amylin receptor agonist, now named zenagamtide. It is not FDA-approved.","field":"Profile summary"},{"after":"Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects. Phase 3 trials registered as zenagamtide have not reported results.","before":"Published randomized trials, each with fewer than 300 participants, report weight loss in early studies and lower HbA1c in a Phase 2 diabetes trial, with common gastrointestinal side effects.","field":"Evidence note"},{"after":"ctg-nct06049329-v6, journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080, ctg-observation-nct07668401-2026-08-24-5833a93b62ac, ctg-observation-nct07720271-2026-09-28-93ed8b5caeb7, ctg-observation-nct07797335-2026-09-01-bc9e4b3246b2, ctg-observation-nct07861100-2026-10-06-c1032ee418d6, ctg-observation-nct07931495-2026-11-12-23a664ffa2bf, ctg-observation-nct07931547-2026-11-12-2d2f13db63aa","before":"ctg-nct06049329-v6, journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080","field":"Cited source records"},{"after":"name: ctg-nct06049329-v6; aliases: ctg-nct06049329-v6, journal-pmid-42532080; category: ctg-nct06049329-v6; status: ctg-nct06049329-v6, journal-pmid-42532080; summary: ctg-nct06049329-v6, journal-pmid-42532080, ctg-observation-nct07668401-2026-08-24-5833a93b62ac, ctg-observation-nct07720271-2026-09-28-93ed8b5caeb7, ctg-observation-nct07797335-2026-09-01-bc9e4b3246b2, ctg-observation-nct07861100-2026-10-06-c1032ee418d6, ctg-observation-nct07931495-2026-11-12-23a664ffa2bf, ctg-observation-nct07931547-2026-11-12-2d2f13db63aa; evidenceNote: journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080, ctg-observation-nct07668401-2026-08-24-5833a93b62ac, ctg-observation-nct07720271-2026-09-28-93ed8b5caeb7, ctg-observation-nct07797335-2026-09-01-bc9e4b3246b2, ctg-observation-nct07861100-2026-10-06-c1032ee418d6, ctg-observation-nct07931495-2026-11-12-23a664ffa2bf, ctg-observation-nct07931547-2026-11-12-2d2f13db63aa","before":"name: ctg-nct06049329-v6; aliases: ctg-nct06049329-v6, journal-pmid-42532080; category: ctg-nct06049329-v6; status: ctg-nct06049329-v6, journal-pmid-42532080; summary: ctg-nct06049329-v6, journal-pmid-42532080; evidenceNote: journal-pmid-40550229, journal-pmid-40550231, journal-pmid-42532080","field":"Claim citations"}],"currentVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/amycretin/versions/4/","version":4},"id":"profile:amycretin:v4","interpretationBoundary":"This event describes a PeptideScanner public-version change. It does not by itself establish that the cited source changed, that a scientific conclusion changed, or that source monitoring is continuous.","kind":"profile-updated","notice":"We added the six Novo Nordisk Phase 3 trials that ClinicalTrials.gov lists under the name zenagamtide, which the previous version did not describe, from registry records PeptideScanner retained on November 15, 2026.","peptideSlugs":["amycretin"],"previousChangeEvent":{"path":"/corrections/v1/profiles/amycretin/v3.json","sha256":"4858675872fab072ae32bb20befd743ebd07b4cc70334efb20cefdbdaccb10ce"},"previousVersion":{"canonicalUrl":"https://peptidescanner.com/peptides/amycretin/versions/3/","version":3},"schemaVersion":"peptidescanner-public-correction-lineage-event/v1","sourceRecords":[{"id":"ctg-observation-nct07668401-2026-08-24-5833a93b62ac","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07668401 · retained source version 2026-08-24:5833a93b62ac59e564069a1fd4bf8cd19222029a0b3f7ce99899f59f22b177dc","url":"https://clinicaltrials.gov/study/NCT07668401","verifiedAt":"2026-11-15"},{"id":"ctg-observation-nct07720271-2026-09-28-93ed8b5caeb7","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07720271 · retained source version 2026-09-28:93ed8b5caeb775d7d6fbd3c0d4e0c5ce26698ea8c1ae70efd4b447411785d74d","url":"https://clinicaltrials.gov/study/NCT07720271","verifiedAt":"2026-11-15"},{"id":"ctg-observation-nct07797335-2026-09-01-bc9e4b3246b2","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07797335 · retained source version 2026-09-01:bc9e4b3246b2a07cc90834c13fa40cb6e95033b38aa14b8b29396518aff35b74","url":"https://clinicaltrials.gov/study/NCT07797335","verifiedAt":"2026-11-15"},{"id":"ctg-observation-nct07861100-2026-10-06-c1032ee418d6","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07861100 · retained source version 2026-10-06:c1032ee418d61646c75ff354e74a7285b9376c0eaeb82c0622036ec003177db0","url":"https://clinicaltrials.gov/study/NCT07861100","verifiedAt":"2026-11-15"},{"id":"ctg-observation-nct07931495-2026-11-12-23a664ffa2bf","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07931495 · retained source version 2026-11-12:23a664ffa2bff21e8dd34305b3456a3ee5f65f216d24ab4d40b786451213bde4","url":"https://clinicaltrials.gov/study/NCT07931495","verifiedAt":"2026-11-15"},{"id":"ctg-observation-nct07931547-2026-11-12-2d2f13db63aa","name":"ClinicalTrials.gov","sourceClass":"A","title":"ClinicalTrials.gov record NCT07931547 · retained source version 2026-11-12:2d2f13db63aaf8b3fc36fdb710419bcd545343ee84a805e746017fc30430e350","url":"https://clinicaltrials.gov/study/NCT07931547","verifiedAt":"2026-11-15"}],"subject":{"slug":"amycretin","type":"profile"}}
